Abstract
Purpose: :
To report the visual outcome and ocular complications of an intravitreal injection of triamcinolone (IVT) in the treatment of macular edema secondary to parafoveal telangiectasis (PFT) type 2A.
Methods: :
Multicenter retrospective case series of 19 eyes from 14 patients with macular edema secondary to PFT type 2A that had undergone an intravitreal injection of 4 mg of triamcinolone.
Results: :
At baseline, 5.3% (1/19) had a visual acuity of 20/40 or better, 47.3% (9/19) between 20/50, and 20/160, 47.3% (9/19) worse than 20/200. Patients were followed for an average of 17.3 months (range 5–32 months). At the last follow up after IVT, 31.6% (6/19) improved 2 or more lines of vision, 57.9% (11/19) remained within 2 lines of baseline visual acuity, 10.5% (2/19) lost 2 or more lines of vision. In addition, 16% (3/19) had 20/40 or better, 42% (8/19) had between 20/50 and 20/160, and 42% (8/19) had 20/200 or worse. Seven eyes were reinjected once. No cases of retinal detachment, vitreous hemorrhage or endophthalmitits were reported. However 53% (10/19) developed cataract (one case required phacoemulsification and intraocular lens implantation) and 21% (4/19) had an elevated intraocular pressure, none of which required surgical treatment.
Conclusions: :
Intravitreal triamcinolone does not seem to have a long term beneficial effect in most eyes with macular edema secondary to PFT type 2A.
Keywords: macula/fovea • retina • clinical (human) or epidemiologic studies: outcomes/complications